Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028.
CADL · Candel Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Candel Therapeutics said it became aware on November the 9th that validation of its potency assay would take six months. The company said the delay is analytical rather than manufacturing-related, and the coefficient of variability must be consistently lower than 30%. Launch is now targeted for Q1, 2028, and the cash runway extends into the second quarter of 2028.
On November 12, 2026, Candel Therapeutics, Inc. entered a new at-the-market agreement with Jefferies LLC for up to $50,000,000 of common stock, after selling approximately $50,000,000 under its 2025 agreement. Jefferies receives a 3.0% commission on gross proceeds.
Candel Therapeutics said aglatimagene achieved a 39% improvement in prostate cancer-specific disease-free survival at 58.0 months median follow-up, plans a BLA submission in the middle of 2027, and paused pancreatic cancer development.
Candel Therapeutics plans to submit aglatimagene’s prostate cancer BLA in the middle of 2027 pending FDA dialogue, while $203.1 million in cash is expected to fund operations into Q2 2028. Third-quarter 2026 net loss widened to $21.9 million from $11.3 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Median follow-up (Arms A+B, linoserpaturev rHGG phase 1b) | 68.6 | Q3 2026 | — |
| Median overall survival (mOS), phase 2a aglatimagene plus valacyclovir in stage III/IV NSCLC | 24.5 | Q3 2026 | — |
| mOS (Arm C, linoserpaturev rHGG phase 1b) | 14.3 | Q3 2026 | — |
| mOS (Arms A+B, linoserpaturev rHGG phase 1b) | 12 | Q3 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CADL
this stock
Candel Therapeutics, Inc.
|
$402.43M | -9.2% | +0.0% | — | 16.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 26
Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CADL | -38.9% | -38.8% | -39.7% | -38.4% | -9.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -33.4% | -32.5% | -34.1% | -33.2% | -14.2% |